



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Francis KALUSH et al.

Art Unit:

Serial No.: 09/768,185

Examiner:

Filed: January 24, 2001

Atty. Docket: CL000280

TECH CENTER 1600/2900

DEC 06 2001

RECEIVED

For: ESTROGEN RECEPTOR BETA VARIANTS AND
METHODS OF DETECTION THEREOF

**Statement Regarding Duty to Disclose Information Material To
Patentability Under 37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

By Facsimile

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

This Information Disclosure Statement is being filed no later than three months from the application filing date of before the mailing date of the first Office Action on the merits, and therefore no Statement under 37 CFR \$1.17(p) is required.

Respectfully submitted,
CELERA GENOMICS

Date: October 24, 2001

By: Robert A. Millman
Robert A. Millman, Reg No. 36,217

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084